Literature DB >> 7967597

Adenosine's effect on myocardial functional recovery: substrate or signal?

S F Bolling1, K F Childs, X H Ning.   

Abstract

During induced ischemia for cardiac surgery, nucleotides are degraded while being used to maintain myocyte integrity. The resulting nucleosides washout upon reperfusion, limiting nucleotide resynthesis resulting in poor postischemic cardiac function. We studied if the mechanism of the beneficial effect of adenosine, a nucleotide precursor, which is known to improve postischemic functional recovery is as a substrate for nucleotide resynthesis or by stimulation of adenosine A1 or A2 receptors. Isolated, retrograde-perfused rabbit hearts received cardioplegia as controls or cardioplegia containing 80 microM [R]-N6-[1-methyl-2-phenylethyl]-adenosine, an A1 receptor agonist, or 200 microM 5'-(N-ethylcarboxamido)adenosine, or 200 microM adenosine alone. To assess functional recovery developed pressure, max dP/dt, pressure-rate product, coronary flow, and myocardial oxygen consumption were compared after 120 min of 34 degrees C global cardioplegic ischemia. Following ischemia and reperfusion, adenosine alone had better developed pressure, dP/dt, and pressure-rate product, while heart rates, wet weights, %H2O, end-diastolic volumes/pressures, and oxygen extraction were not significantly different between groups. While adenosine receptor stimulation may play a role, in this model the beneficial effect of adenosine on functional recovery appears to be mediated more by adenosine's role as a substrate for nucleotide resynthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7967597     DOI: 10.1006/jsre.1994.1188

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  1 in total

1.  Adenosine in cold blood cardioplegia--a placebo-controlled study.

Authors:  Anders Ahlsson; Claudio Sobrosa; Lennart Kaijser; Eva Jansson; Vollmer Bomfim
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.